Central Memory T Cell Enrichment for Adoptive Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The efficacy of adoptive immunotherapy using cultured CD8+ T cells is limited by their poor persistence after transfer due to differentiation into short-lived cytolytic effector cells during in vitro culture, which are destined to die, leading to reduced therapeutic effectiveness in clinical applications.
Innovation Solution
A method involving the administration of a cytotoxic T lymphocyte (CTL) preparation enriched for central memory T lymphocytes and depleted of effector memory T lymphocytes, with concurrent administration of Interleukin-15 to enhance proliferation, is used to improve the persistence and function of T cells in a primate subject.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If CD8+ T cells are cultured in vitro to expand their numbers for adoptive immunotherapy, then the quantity of T cells increases, but the cells differentiate into short-lived effector cells that die quickly after transfer
Solution Approach 1:
The patent applies preliminary action by selecting and expanding central memory T cells (TCM) before adoptive transfer. TCM cells are precursors that can be expanded in vitro while maintaining their memory phenotype and long-term persistence capacity. By performing the selection and expansion of the correct cell subset beforehand, the patent ensures both sufficient cell numbers and long-term survival after transfer, resolving the contradiction between quantity and duration.
2Reliability
If effector memory T cells are used for adoptive transfer, then immediate cytolytic function is achieved, but the cells have poor survival and short persistence
Solution Approach 1:
The patent segments the T cell population into distinct functional subsets: central memory T cells (TCM) for long-term persistence and effector memory T cells (TEM) for immediate cytolytic function. By separating these functions into different cell subsets and selectively expanding TCM, the patent achieves both immediate function (from the small TEM component or rapid differentiation of TCM) and long-term survival (from the expanded TCM pool), resolving the contradiction between reliability and duration.
3Quantity of substance
If T cells are expanded in vitro for several weeks to achieve sufficient numbers, then the cell quantity is adequate for therapy, but the cells lose their memory phenotype and differentiate into effector cells
Solution Approach 1:
The patent applies parameter changes by optimizing culture conditions specifically for central memory T cell expansion. This includes using cytokine combinations (such as IL-7 and IL-15) and culture protocols that maintain TCM phenotype markers (CD62L, CCR7) during in vitro expansion. By changing the cultural parameters to favor TCM maintenance, the patent achieves both sufficient cell numbers and preservation of memory phenotype, resolving the contradiction between quantity and compositional stability.
Data Source
AI summary
The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.